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Background: Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia
chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more
intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased
morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been
proven to be a strong prognostic factor for adult patients with Ph-negative ALL.
Methods: We investigated whether MRD status in adult patients with ALL is useful to decide clinical indications for
allogeneic HSCT. We prospectively monitored MRD after induction and consolidation therapy in adult patients with
Ph-negative ALL.
Results: Of 110 adult ALL patients enrolled between July 2002 and August 2008, 101 were eligible, including 59
Ph-negative patients. MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and
Ig and the presence of chimeric mRNA. Thirty-nine patients achieved CR1, and their probabilities of 3-year overall
survival and disease-free survival (DFS) were 74% and 56%, respectively. Patients who were MRD-negative after
induction therapy (n = 26) had a significantly better 3-year DFS compared with those who were MRD-positive
(n = 13; 69% vs. 31%, p = 0.004). All of 3 patients who were MRD-positive following consolidation chemotherapy
and did not undergo allogeneic HSCT, relapsed and died within 3 years after CR.
Conclusions: These results indicate that MRD monitoring is useful for determining the clinical indications for
allogeneic HSCT in the treatment of ALL in CR1.
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Although more than 80% of adult patients with Philadelphia
chromosome (Ph)-negative acute lymphoblastic leukemia
(ALL) achieve complete remission (CR) with conventional
induction therapy, their 5-year survival is only 30%–40%.
Leukemia relapse is the most common cause of treatment
failure in ALL [1-6]. Therefore, post-remission therapy is* Correspondence: knagafuji@med.kurume-u.ac.jp
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reproduction in any medium, provided the ornecessary and should be optimized in the treatment of
adult ALL patients. If prognosis of patients with ALL in
CR1 is estimated to be favorable, chemotherapy is usually
continued to prevent leukemia relapse. However, patients
with less favorable prognosis should be treated more ag-
gressively [7]. Although allogeneic hematopoietic stem cell
transplantation (HSCT) for patients with ALL in CR1 is
much more intensive than multi-agent combined chemo-
therapy, it is associated with increased morbidity and mor-
tality when compared with such chemotherapy.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to be a strong prognostic factor for adult patients with Ph-
negative ALL [8-14]. In this study, we prospectively moni-
tored the MRD status after CR induction and consolidation
chemotherapies in adult patients with Ph-negative ALL to
determine the clinical indications for allogeneic HSCT.
Patients & methods
Patient eligibility criteria
A total of 110 adult ALL patients were enrolled in this
study between July 2002 and August 2008 on the basis
of the following eligibility criteria: non-L3 ALL, 16–65
years of age, an Eastern Cooperative Oncology Group
performance status of 0–2, and adequate liver and kid-
ney function (serum bilirubin, ≤2.0 mg/dl and serum
creatinine, ≤2.0 mg/dl, respectively). Cytogenetic studies
were performed on pretreated bone marrow or unstimu-
lated blood samples using the standard banding tech-
nique. The treatment protocol was approved by the
institutional review board of each participating hospital.
Written informed consent was obtained from all patients
in accordance with the Declaration of Helsinki. Of the
110 patients enrolled, 42 were excluded from the study
because of Ph-positivity, 5 because of misdiagnosis, 2 be-
cause of infectious complications, and 1 each because of
liver damage and protocol violation. The remaining 59
patients were Ph-negative.
Treatment
We used a modified CALGB 19802 [15,16] treatment
protocol that comprised 6 courses of chemotherapy admi-
nistered in the order of A-B-C-A-B-C regimens, followed
by a maintenance phase. Induction chemotherapy (course
A) was a 21-day course consisting of cyclophosphamide
(CPM; 1200 mg/m2 on day 1), daunorubicin (DNR; 60 mg/
m2 on days 1, 2, and 3), vincristine (VCR;1.3 mg/m2 [max-
imum 2 mg] on days 1, 8, 15, and 22), L-asparaginase
(3000 U/m2 on days 9, 11, 13, 16, 18, and 20), and prednis-
olone (PSL; 60 mg/m2 [max 100 mg]). Granulocyte-colony
stimulating factor (nartograstim) was administered starting
from day 4 and continued until neutrophil recovery. For
patients aged 55 years or older, the doses of CPM and
DNR were reduced to 500 mg/m2 and 50 mg/m2, respect-
ively. Furthermore, PSL therapy was shortened to 7 days in
these patients. The first consolidation therapy (course B)
consisted of mitoxantrone (MIT; 10 mg/m2 on days 2 and
3), cytarabine (AraC; 2000 mg/m2/day on days 1, 2, 3, and
4) and intrathecal administration of methotrexate (MTX;
15 mg/body on day 1). For patients aged 55 years or older,
the doses of MIT and AraC were reduced to 7 mg/m2
and 1500 mg/m2/day, respectively. The second consoli-
dation therapy (course C) consisted of VCR (1.3 mg/m2
[max 2 mg] on days 1, 8, and 15) and MTX (1500 mg/m2
on days 1, 8, and 15) with leucovorin rescue and intrathecalMTX on days 1, 8, and 15. The patients received the fol-
lowing maintenance chemotherapy on a monthly basis:
PSL, 60 mg/m2 on days 1–5; VCR, 1.3 mg/m2 (max 2 mg)
on day 1; oral MTX, 20 mg/m2 weekly; and oral 6-mercap-
topurine, 60 mg/m2 daily. MRD status was evaluated after
the induction therapy (first course A) and after the second
consolidation therapy (first course C). Patients with posi-
tive MRD following the second consolidation therapy were
considered to be indicated for allogeneic HSCT as soon as
possible. Eligible donors included HLA-identical related,
HLA-identical unrelated donors from Japan Marrow Do-
nation Program, and cord blood from Japan Cord Blood
Bank Network. Conditioning before allogeneic HSCT and
prophylaxis for graft-versus-host disease was performed
according to each institutional standard.
MRD analysis
Real-time quantitative polymerase chain reaction (RQ-PCR)
analysis of chimeric mRNA
mRNA from bone marrow cells were analyzed for the
presence of major and minor BCR/ABL, TEL/AML1,
MLL/AF4, MLL/AF9, MLL/AF6, MLL/ENL, E2A/PBX1,
and SIL/TAL1 chimeric genes. Samples were amplified
by RQ-PCR and quantified by parallel amplification of
serial dilutions of transcript-containing plasmids [17,18].
PCR analysis of TCR/Ig rearrangement
High-molecular weight DNA from marrow cells was ini-
tially screened for major rearrangement patterns of TCRγ,
TCRδ, and Igκ, and secondarily screened for rearrange-
ments in Ig heavy chain (IgH), using previously described
primers [19-21]. Two-step (nested) PCR for MRD quanti-
fication was performed using allele-specific oligonucleo-
tide (ASO)-primers based on the sequence of PCR
screening products, which had clonal recombinations by
heteroduplex analyses. Prior to PCR analysis, DNA sam-
ples from post-treatment bone marrow samples and DNA
from the samples obtained at diagnosis were serially
diluted (between 10−2 and 10−5) with buffy coat DNA
from eight healthy volunteers. Buffy coat DNA was also
used as a control for nonspecific amplification of compar-
able Ig/TCR arrangements present in normal cells. All
PCR reactions were performed simultaneously and ana-
lyzed using ethidium staining and agarose gel electrophor-
esis. MRD was quantified by comparing the intensities of
band signals on an agarose gel stained with ethidium
bromide without amplification of the background. MRD
quantifications were performed using ASO-primers with a
sensitivity of ≤1 × 10−4, and MRD positivity was defined as
a lower limit of detection of ≥1 × 10−3.
Statistical analysis
Statistical analyses of the data accumulated throughout
October 2011 were performed. Overall survival (OS) was
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the trial or death, and disease-free survival (DFS) was
defined as the time from CR to relapse or death while
still in CR. Survival curves were estimated using the
Kaplan–Meier method, and the statistical significance of
differences in survival was determined using the log-
rank test.
The influence of prognostic factors including age,
white blood cell (WBC) count, and MRD status on DFS
was estimated with multivariate Cox regression analysis.
The level of statistical significance was set at 0.05.
Results
Treatment outcome
The median follow-up time was 1134 days (range, 14–3248
days). A total of 59 patients were Ph-negative (29 males
and 30 females), and their median age was 35 years ranging
from 16 to 63. The median white blood cell count at pres-
entation was 11.0 × 103/L (range 0.9–409). CR was achieved
in 47 patients (80%). Six patients died during induction;
their causes of death included sepsis (n = 3), pneumonia
(n = 2), and other (n = 1). There were 29 survivors after the
median follow-up period. The probability of 3-year OS and
DFS in these patients with Ph-negative ALL was 59% and
52%, respectively (Table 1).
Relationship between MRD status and treatment
outcomes
Among the 59 Ph-negative ALL patients, 43 patients (73%)
could be monitored for MRD status, and the remaining 16
patients were not because 10 had no clonal TCR/Ig targets
or chimeric mRNA and 6 did not provide sufficient DNA
or RNA from their samples. The MRD status of 43 patientsTable 1 Patient characteristics and clinical outcome
Ph negative Ph negative
& known
MRD status
Total No. patients 59 43
Sex, No. (%)
Male 29 (49) 21 (49)
Female 30 (51) 22 (51)
Median Age, (range) 35 (16-63) 31 (17-63)
Median WBC count, ×109/L, (range) 11.0 (0.9-409) 10.6 (1-409)
Immunophenotype, No. (%)
B-lineage 45 (76) 36 (84)
T-lineage 14 (24) 7 (16)
CR rate, No. (%) 47 (80) 39 (91)
3-years OS (%) 59 74
3-years DFS (%) 52 56
MRD, minimal residual disease; Ph, Philadelphia chromosome; CR, complete
remission; OS, overall survival; DFS, disease-free survival.(21 males and 22 females; median age: 31 years, ranging
from 17 to 63; median WBC count at presentation: 10.6 ×
103/L ranging 1–409) was determined by PCR analysis of
major gene rearrangements and/or chimeric mRNAs (15
were positive for TCRγ, 6 for TCRδ, 6 for Igκ, 11 for IgH, 1
for TCRγ and TCRδ, 1 for TCRδ and IgH, 1 for E2A-PBX,
1 for MLL-AF4, and 1 for MLL-ENL). CR was achieved in
39 of these 43 patients with known MRD status (91%). The
median follow-up time was 1421 days (range, 162–3248
days). The probability of 3-year OS and DFS in the
Ph-negative patients with known MRD status was 74% and
56%, respectively (Table 1). In terms of CR1 status, MRD-
negative patients after induction chemotherapy A in the
first course (n = 26) showed a better 3-year DFS (69%)
compared with MRD-positive patients (n = 13; 31%), as
shown in Figure 1. The difference was statistically signifi-
cant (p = 0.004). MRD-negative patients also showed a
significantly lower 3-year relapse rate compared with
MRD-positive patients (28% vs. 58%, p = 0.031).
There was no patient who proceeded to allogeneic
HSCT among 26 MRD-negative patients after induction
therapy in CR. In contrast, patients who were MRD-
positive after induction but became MRD-negative after
consolidation chemotherapy C in the first course (n = 7)
showed a significantly worse 3-year DFS compared with
patients who were MRD-negative after induction chemo-
therapy A in the first course (29% vs. 69%, p = 0.004), as
shown in Figure 2. Among 7 late-attained MRD-negative
patients, three patients proceeded to allogeneic HSCT
when MRD status became positive again under mainten-
ance therapy. Six patients were MRD-positive after con-
solidation chemotherapy C in the first course, and 3
patients among them proceeded to allogeneic HSCT,
while other 3 patients did not because of lack of a suitable
donor (n = 1) and of patients’ refusal to allogeneic HSCT
(n = 2). All of 3 MRD-positive patients who did not
undergo allogeneic HSCT, relapsed and died within 3
years after CR, whereas 2 of 3 patients those who received
allogeneic HSCT gave DFS at 3 years. Table 2 shows the
results of multivariate Cox regression analysis for DFS in
43 MRD-evaluable patients. The analysis indicates that
age (≥35 years vs. <35 years: Hazard ratio (HR) 5.067, and
p = 0.005) and MRD status after induction therapy (posi-
tive vs. negative: HR 8.769, and p < 0.001) were significant
prognostic factors, whereas WBC count (≥30 × 109/L vs.
<30 × 109/L: HR 1.496, and p = 0.505) or MRD status after
consolidation therapy (positive vs. negative: HR 0.675, and
p = 0.556) was not.
Discussion
Compared with treatments for childhood ALL, those for
adult ALL are far less effective [22], and allogeneic
HSCT is frequently recommended as the most potent
post-remission therapy for ALL patients in CR1 [23].
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Figure 1 Impact of post-induction minimal residual disease (MRD) status on overall survival (OS) and disease-free survival (DFS).
Patients who were MRD negative after induction therapy (first course A) (n = 26) had a significantly better 3-year DFS compared with those who
were MRD positive (n = 13) (69% vs. 31%, p = 0.004).
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sis [24-26], the notion that allogeneic HSCT should be
performed for all patients with ALL beyond CR1 is diffi-
cult to be realized in clinical situations [7].
The international ALL trial MRC UKALL XII/ECOG
E2993 showed that allogeneic HSCT using matched
related donors provided survival benefit for standard-
risk adult patients with Ph-negative ALL in CR1 com-
pared with chemotherapy, while there was no significant
survival benefit for high-risk patients. Allogeneic HSCT
is able to reduce relapse rates in both standard-risk and
high-risk patients; however, there is a decrease in OS in
the high-risk patients because of their higher rates of
transplant-related mortality. The high-risk in this inter-
national study was defined as having as 1 of the follow-
ing factors: age more than 35 years, a high WBC count
at presentation (>30 × 109/L for B lineage and >100 ×
109/L for T lineage) [23]. Age is a significant prognostic
factor for ALL patients receiving allogeneic HSCT asMRD +
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Figure 2 Effect of time taken to become minimal residual disease (MR
positive after induction and became MRD negative after consolidation che
compared with patients who were MRD negative after induction chemothwell as chemotherapy [27]. Therefore, allogeneic HSCT
may not be a recommended option for patients defined
as high-risk because of their age being more than 35
years old [28,29].
Recent studies have shown that a pediatric-inspired
ALL chemotherapy protocol significantly improves treat-
ment outcome in relatively young adult ALL patients
[30-34], and this patient population is at standard-risk in
terms of age. Thus, the indication of allogeneic HSCT
based on the risk stratification made by initial presenta-
tion needs to be tested, and more reliable indication for
allogeneic HSCT in adult patients with Ph-negative ALL
in CR1 is necessary.
MRD measurement in adult patients with Ph-negative
ALL has been reported to be useful for identifying patients
with a significantly high risk of relapse. The German
Multicenter Study Group for adult ALL (GMALL) study
used PCR analysis of antigen-receptor genes to assess
MRD in standard-risk ALL patients. Low-risk patients after induction & MRD – after consolidation






D)-negative on disease-free survival (DFS). Patients who were MRD
motherapy C in the first course (n = 7) had a significantly worse DFS
erapy A in the first course (n = 26) (69% vs. 29%, p = 0.004).
Table 2 Multivariate analysis for disease-free survival
(Cox Regression Model)
Hazard ratio 95% CI P-value
Risk factors
Age 5.067 1.616 15.885 0.005
WBC 1.496 0.457 4.897 0.505
MRD status after induction 8.769 2.465 31.196 <0.001
MRD status after consolidation 0.67 0.18 2.492 0.55
Age: ≥35 vs <35.
WBC: ≥30×109/L vs <30×109/L.
MRD after Induction: positive vs. negative.
MRD after consolidation: positive vs. negative
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had a 3-year relapse rate of 0%; high-risk patients were
those with MRD-positive until week 16 and had a relapse
rate of 94% [10]. The Northern Italy Leukemia Group-
ALL 09/00 study found that MRD was the most signifi-
cant predictor of relapse [13]. The estimated 5-year DFS
was 72% in 58 MRD-negative patients at the end of con-
solidation and 14% in 54 MRD-positive patients.
Our results indicate that patients with MRD negativity
after induction therapy provided excellent DFS without
allogeneic HSCT, whereas patients with MRD positivity
after several consolidation therapies showed very poor DFS
if they did not undergo allogeneic HSCT. This observation
is in line with above reports. Our analysis showed that late-
attained MRD negativity could not lead to good prognosis,
while other groups reported the MRD negativity at the end
of consolidation to be associated with good prognosis. This
controversy may reflect the sensitivity level of MRD meas-
urement. We used semi-quantitative PCR analysis and
defined MRD negativity as <1 × 10−3, whereas GMALL [10]
and The Northern Italy Leukemia Group-ALL 09/00 study
[13] analyzed MRD according to EuroMRD-ALL guidelines
[35,36] and considered <1 × 10−4 as MRD negativity. In
our study, MRD positivity after the second course of con-
solidation was seen in 6 of 37, while MRD positivity at the
end of consolidation was observed in 54 of 112 in The
Northern Italy Leukemia Group-ALL study 09/00 [13].
Thus, our MRD-negative patients had a possibility of
MRD positivity if more sensitive MRD analysis was used.
We suggest these late-attained MRD-negative patients
were potential candidates for allogeneic HSCT.
In this study, the results of multivariate Cox regression
analysis for DFS indicates that age (≥35 years vs. <35
years) and MRD status after induction therapy were sig-
nificant prognostic factors, whereas WBC count (≥30 ×
109/L vs. <30 × 109/L) or MRD status after consolidation
therapy was not. Age is one of the most important prog-
nostic factors in adult ALL patients, and age of our
study population was median 31 years-old ranging 17 to
63 including adolescent and young adult patients. Thus,
these relative young patients were supposed to havegood prognosis with chemotherapy. Initial WBC count
has been another important prognostic factor in adult
ALL patients, but not in our study. Our chemotherapy
regimen was modified CALGB 19802 with dose intensi-
fication of daunorubicin and cytarabine, and it might be
possible that this intensive chemotherapy conquer nega-
tive impact of high initial WBC count. According to the
recently reported result of CALGB 19802 [16], age (≥60
years vs. <60 years) was a significant prognostic factor
for DFS, while initial WBC count (≥30 × 109/L vs. <30 ×
109/L) was not. This report was in line with our observa-
tion. In our analysis MRD status after induction therapy
(positive vs. negative: HR 8.769, and p < 0.001) was a
very strong prognostic factor for DFS. Whether negative
impact of MRD positivity could be overcome by allogen-
eic HSCT is the next consideration. There are two
reports regarding the effect of prospective allocation for
allogeneic HSCT based on MRD positivity in adult
patients with Ph-negative ALL in CR1.
In the Northern Italy Leukemia Group-ALL study 09/00,
for the MRD-positive patients at the end of consolidation,
there was a significantly better 4-year DFS for 36 patients
who had an allogeneic (n = 22) and autologous (n = 14)
HSCT compared to 18 patients unable to undergo HSCT
(33% vs. 0%, p = 0.0000) [13]. The GMALL reported that
5-year DFS for MRD-positive patients at week 16 with
(n = 57) vs. without (n = 63) allogeneic HSCT were 44 ± 8%
vs. 11 ± 4% respectively (p <0.0001) [37]. In our study,
among MRD-positive patients following consolidation
chemotherapy C in the first course, all of 3 patients with-
out allogeneic HSCT relapsed while 1 of 3 patients with
allogeneic HSCT did. The size of our study population
was too small for statistical analysis. However, these three
studies clearly indicate that MRD-positive patients at late
phase of chemotherapy have little chance of DFS more
than 10% without allogeneic HSCT [37]. These MRD-
defined high-risk patients had much worse prognosis
compared with conventional high-risk patients defined by
initial presentation. Furthermore, allocation of allogeneic
HSCT could improve the prognosis of MRD-defined high-
risk patients.
The interpretation of our results may be affected by a
limited number of adult ALL patients. A role of MRD
measurement should be evaluated in relation with patients’
geography, chemotherapy regimens used, and timing and
sensitivity of MRD analysis. With our less sensitive MRD
analysis compared to EuroMRD-ALL guidelines, we could
identify patients with good early treatment response not
indicated for allogeneic HSCT, while we could not identify
patients with good late treatment response. In near future,
the assessment of MRD status using standardized proto-
cols and RQ-PCR [35,36] will be a valuable tool to stratify
a risk of relapse in adult patients with Ph-negative ALL
in CR1.
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at least twice after induction and consolidation is very use-
ful when considering clinical indication for allogeneic
HSCT in adult patients with Ph-negative ALL in CR1.
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